PRPH Stock Overview
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ProPhase Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.44 |
| 52 Week High | US$9.94 |
| 52 Week Low | US$4.05 |
| Beta | -0.27 |
| 1 Month Change | 4.02% |
| 3 Month Change | 9.90% |
| 1 Year Change | -28.52% |
| 3 Year Change | 13.33% |
| 5 Year Change | 81.03% |
| Change since IPO | 988.00% |
Recent News & Updates
Recent updates
Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?
Mar 04
ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry
Jan 09ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate
Sep 21Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt
Aug 11We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease
Apr 07ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly
Jan 24ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential
Oct 13ProPhase Labs Q2 2022 Earnings Preview
Aug 10We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt
Jul 26ProPhase Labs to license two investigational cancer compounds from Global BioLife
Jul 21ProPhase Labs: A Stellar Quarter And Another Special Dividend
May 16ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 08ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely
Mar 23Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt
Nov 30As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit
Oct 20Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Jul 22ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants
Jun 28Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More
May 14ProPhase Labs partners with Dutchess County New York to provide COVID-19 testing
May 06A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Apr 12ProPhase Labs opens Covid testing facility in New York
Jan 29ProPhase Labs announces $5.5M registered direct offering of common stock and warrants
Jan 05ProPhase Labs expands COVID-19 testing capacity in New York, shares +21%
Dec 09Shareholder Returns
| PRPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -15.0% | -2.3% | -3.7% |
| 1Y | -28.5% | 11.4% | 20.2% |
Return vs Industry: PRPH underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: PRPH underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| PRPH volatility | |
|---|---|
| PRPH Average Weekly Movement | 10.3% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRPH's share price has been volatile over the past 3 months.
Volatility Over Time: PRPH's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 113 | Ted Karkus | www.prophaselabs.com |
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
ProPhase Labs, Inc. Fundamentals Summary
| PRPH fundamental statistics | |
|---|---|
| Market cap | US$98.17m |
| Earnings (TTM) | -US$16.78m |
| Revenue (TTM) | US$44.38m |
2.2x
P/S Ratio-5.8x
P/E RatioIs PRPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRPH income statement (TTM) | |
|---|---|
| Revenue | US$44.38m |
| Cost of Revenue | US$28.15m |
| Gross Profit | US$16.24m |
| Other Expenses | US$33.02m |
| Earnings | -US$16.78m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.93 |
| Gross Margin | 36.59% |
| Net Profit Margin | -37.81% |
| Debt/Equity Ratio | 20.8% |
How did PRPH perform over the long term?
See historical performance and comparison